Advanced search
Publication Cover
Renal Failure Volume 36, 2014 - Issue 2
Submit an article Journal homepage
2,432
Views
29
CrossRef citations to date
0
Altmetric
Research Article

Febuxostat for treating allopurinol-resistant hyperuricemia in patients with chronic kidney disease

Yukinao SakaiDivision of Nephrology, Department of Internal Medicine, Nippon Medical School Musashikosugi Hospital KawasakiJapanCorrespondence[email protected]
,
Tomoyuki OtsukaDivision of Nephrology, Department of Internal Medicine, Nippon Medical School Musashikosugi Hospital KawasakiJapan
,
Dai OhnoDivision of Nephrology, Department of Internal Medicine, Nippon Medical School Musashikosugi Hospital KawasakiJapan
,
Tsuneo MurasawaDivision of Nephrology, Department of Internal Medicine, Nippon Medical School Musashikosugi Hospital KawasakiJapan
,
Naoki SatoDivision of Cardiology, Department of Internal Medicine, Nippon Medical School Musashikosugi Hospital KawasakiJapan
&
Shuichi TsuruokaDivision of Nephrology, Department of Internal Medicine, Graduate School of Medicine, Nippon Medical School TokyoJapan
Pages 225-231 | Received 25 Jul 2013, Accepted 30 Aug 2013, Published online: 24 Oct 2013

Citations (29)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Mohamed Talaat, Kyle Park & Naomi Schlesinger. (2021) Contentious Issues in Gout Management: The Story so Far. Open Access Rheumatology: Research and Reviews 13, pages 111-122.
Read now
Periklis Dousdampanis, Konstantina Trigka, Carlos G. Musso & Costas Fourtounas. (2014) Hyperuricemia and chronic kidney disease: an enigma yet to be solved. Renal Failure 36:9, pages 1351-1359.
Read now

Articles from other publishers (27)

Saksham Matta, Garima Bhutani, Tarun Arora, Renu Garg, Seema Rani & Rahul Saini. (2023) COMPARISON BETWEEN RENOPROTECTIVE EFFECTS OF FEBUXOSTAT AND ALLOPURINOL IN CHRONIC KIDNEY DISEASE PATIENTS WITH HYPERURICEMIA. Asian Journal of Pharmaceutical and Clinical Research, pages 54-58.
Crossref
George J. Schwartz, Jennifer L. Roem, Stephen R. Hooper, Susan L. Furth, Donald J. WeaverJr.Jr., Bradley A. Warady & Michael F. Schneider. (2022) Longitudinal changes in uric acid concentration and their relationship with chronic kidney disease progression in children and adolescents. Pediatric Nephrology 38:2, pages 489-497.
Crossref
See Y. Choi, Seung W. Choi, Sunggun Lee, Min W. So, Ji S. Oh & Doo‐Ho Lim. (2021) Efficacy and tolerability of febuxostat in gout patients on dialysis. Internal Medicine Journal 51:3, pages 348-354.
Crossref
Sang-Hyon Kim, So-Yeon Lee, Ji-Min Kim & Chang-Nam Son. (2020) Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4–5 chronic kidney disease not yet on dialysis. The Korean Journal of Internal Medicine 35:4, pages 998-1003.
Crossref
Yun‐Shiuan O. Hsu, I‐Wen Wu, Shang‐Hung Chang, Cheng‐Chia Lee, Chung‐Ying Tsai, Chan‐Yu Lin, Wan‐Ting Lin, Yu‐Tung Huang, Chao‐Yi Wu, George Kuo, Chih‐Yen Hsiao, Hsing‐Lin Lin, Chih‐Chao Yang, Tzung‐Hai Yen, Yung‐Chang Chen, Cheng‐Chieh Hung, Ya‐Chong Tian, Chang‐Fu Kuo, Chih‐Wei Yang, Gerard F. Anderson & Huang‐Yu Yang. (2019) Comparative Renoprotective Effect of Febuxostat and Allopurinol in Predialysis Stage 5 Chronic Kidney Disease Patients: A Nationwide Database Analysis. Clinical Pharmacology & Therapeutics 107:5, pages 1159-1169.
Crossref
Xinrui Li, Jing Liu, Liang Ma & Ping Fu. (2019) Pharmacological urate-lowering approaches in chronic kidney disease. European Journal of Medicinal Chemistry 166, pages 186-196.
Crossref
Jang-Wook Lee & Kwang-Hoon Lee. (2019) Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease. International Urology and Nephrology 51:3, pages 467-473.
Crossref
Eeunyoung AhnSunggun LeeHan-Na LeeSeung-Geun LeeMin Wook So. (2019) Comparison of Efficacy and Safety of Febuxostat in Gout Patients with Chronic Kidney Disease Stage 3 and Stage 4/5. Journal of Rheumatic Diseases 26:2, pages 118.
Crossref
Takayuki Tsuji, Kazuhisa Ohishi, Asumi Takeda, Daiki Goto, Taichi Sato, Naro Ohashi, Yoshihide Fujigaki, Akihiko Kato & Hideo Yasuda. (2018) The impact of serum uric acid reduction on renal function and blood pressure in chronic kidney disease patients with hyperuricemia. Clinical and Experimental Nephrology 22:6, pages 1300-1308.
Crossref
Tibor Fülöp, Christian A. Koch, Lindsey T. Norris, Betzaida Rodríguez, Tibor Szarvas, Zsolt Lengvárszky, Éva Csongrádi & Mehul P. Dixit. (2018) Uric Acid Control in Advanced Chronic Kidney Disease in a Southeastern US Urban Cohort. Southern Medical Journal 111:9, pages 549-555.
Crossref
. Experimental and Clinical Transplantation 16:4.
Crossref
Pierre-Antoine Juge, Marie-Elise Truchetet, Evangeline Pillebout, Sébastien Ottaviani, Cécile Vigneau, Clotilde Loustau, Divi Cornec, Tristan Pascart, Renaud Snanoudj, Florian Bailly, Emilie Cornec-Le Gall, Thierry Schaeverbeke, Alain Saraux, Philippe Dieudé, René-Marc Flipo, Pascal Richette, Frédéric Lioté, Thomas Bardin, Gérard Chalès & Hang-Korng Ea. (2018) Efficacité et tolérance du fébuxostat chez 73 patients goutteux avec une insuffisance rénale chronique stade 4/5 : étude rétrospective de 10 centres. Revue du Rhumatisme 85:4, pages 370-374.
Crossref
Yu Yang Ai. (2018) Febuxostat in patients with hyperuricemia and severe chronic kidney disease. African Journal of Pharmacy and Pharmacology 12:17, pages 193-201.
Crossref
Kang Wang, Lei Hu & Jian-Kang Chen. (2018) RIP3-deficience attenuates potassium oxonate-induced hyperuricemia and kidney injury. Biomedicine & Pharmacotherapy 101, pages 617-626.
Crossref
Natalia O. Litbarg. 2018. Integrative Medicine. Integrative Medicine 411 421.e11 .
Pierre-Antoine Juge, Marie-Elise Truchetet, Evangeline Pillebout, Sébastien Ottaviani, Cécile Vigneau, Clotilde Loustau, Divi Cornec, Tristan Pascart, Renaud Snanoudj, Florian Bailly, Emilie Cornec-Le Gall, Thierry Schaeverbeke, Alain Saraux, Philippe Dieudé, René-Marc Flipo, Pascal Richette, Frédéric Lioté, Thomas Bardin, Gérard Chalès & Hang-Korng Ea. (2017) Efficacy and safety of febuxostat in 73 gouty patients with stage 4/5 chronic kidney disease: A retrospective study of 10 centers. Joint Bone Spine 84:5, pages 595-598.
Crossref
Sollip Kim, Hyun-Jung Kim, Hyeong-Sik Ahn, Se Won Oh, Kum Hyun Han, Tae-Hyun Um, Chong-Rae Cho & Sang Youb Han. (2017) Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: A systematic review and meta-analysis. Kidney Research and Clinical Practice 36:3, pages 274-281.
Crossref
Aygul Ozdemir & Ayca Inci. (2017) The effect of allopurinol on the progression of chronic kidney disease. Journal of Nephropharmacology 6:2, pages 138-141.
Crossref
Doo-Ho Lim, Ji Seon Oh, Soo Min Ahn, Seokchan Hong, Yong-Gil Kim, Chang-Keun Lee, Seung Won Choi & Bin Yoo. (2016) Febuxostat in Hyperuricemic Patients With Advanced CKD. American Journal of Kidney Diseases 68:5, pages 819-821.
Crossref
Paweł Kochman & Tomasz Stompór. (2016) Gout, hyperuricemia and chronic kidney disease: New treatment possibilities. Polish Annals of Medicine 23:2, pages 195-201.
Crossref
Yukinao Sakai & Shichi Tsuruoka. (2016) Total Management of CKD. Nihon Ika Daigaku Igakkai Zasshi 12:1, pages 7-14.
Crossref
Lynda Ann Frassetto & Suzanne Gibson. (2016) Febuxostat and Increased Dialysis as a Treatment for Severe Tophaceous Gout in a Hemodialysis Patient. Case Reports in Nephrology 2016, pages 1-3.
Crossref
Akira Sezai, Masayoshi Soma, Kin-ichi Nakata, Shunji Osaka, Yusuke Ishii, Hiroko Yaoita, Hiroaki Hata & Motomi Shiono. (2015) Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD). Journal of Cardiology 66:4, pages 298-303.
Crossref
Jing Xiao, Chensheng Fu, Xiaoli Zhang, Dingyu Zhu, Weijun Chen, Yijun Lu & Zhibin Ye. (2015) Soluble monosodium urate, but not its crystal, induces toll like receptor 4-dependent immune activation in renal mesangial cells. Molecular Immunology 66:2, pages 310-318.
Crossref
Yuki Tsuruta, Toshio Mochizuki, Takahito Moriyama, Mitsuyo Itabashi, Takashi Takei, Ken Tsuchiya & Kosaku Nitta. (2014) Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease. Clinical Rheumatology 33:11, pages 1643-1648.
Crossref
K. H. K. Patel & D. J. A. Goldsmith. (2014) Uric acid as a cardiorenal risk factor - ready for prime-time?. International Journal of Clinical Practice 68:7, pages 796-801.
Crossref
Daisuke NAGATA. (2014) The Clinical Effects of New Non-Purine Xanthine Oxidase Inhibitor, Febuxostat, in Patients with Chronic Kidney Disease. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 45:1, pages 31-32.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.